• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Heska Third Quarter 2022 Financial Results and Earnings Call Scheduled for November 8, 2022

    10/18/22 8:00:00 AM ET
    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $HSKA alert in real time by email

    LOVELAND, Colo., Oct. 18, 2022  /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its third quarter 2022 financial performance in a press release before the market opens on Tuesday, November 8, 2022. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results.

    Heska Corporation (PRNewsfoto/Heska Corporation)

    To access the conference call:

    From within the United States, please dial 1-800-239-9838

    From outside of the United States, please dial 1-323-794-2551

    Reference Conference ID: 7035658

    The earnings call will be webcast live from the Company's investor relations website at: Heska Corporation Third Quarter 2022 Earnings Call Webcast.

    A telephonic replay will be available at 2 p.m. ET on November 8th through 11:59 p.m. ET on November 22, 2022 and the webcast will be archived on the Company's website for 90 days.

    To access the replay by telephone:

    From within the United States, please dial 1-844-512-2921

    From outside the United States, please dial 1-412-317-6671

    Reference Replay Pin Number: 7035658

    About Heska

    Heska Corporation (NASDAQ: HSKA) manufactures, develops and sells advanced veterinary diagnostics, informatics, and specialty healthcare solutions through its two business segments: North America and International. Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The North America segment also includes private label vaccine and pharmaceutical production for third-parties, primarily for herd animal health. For more information, please visit www.heska.com.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/heska-third-quarter-2022-financial-results-and-earnings-call-scheduled-for-november-8-2022-301651800.html

    SOURCE Heska Corporation

    Get the next $HSKA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSKA

    DatePrice TargetRatingAnalyst
    1/6/2023$58.00Equal-Weight → Underweight
    Morgan Stanley
    3/1/2022$190.00 → $161.00Equal-Weight
    Morgan Stanley
    2/23/2022$300.00 → $250.00Overweight
    JP Morgan
    1/6/2022$210.00Overweight
    Piper Sandler
    11/18/2021$190.00Equal-Weight
    Morgan Stanley
    8/4/2021$240.00 → $305.00Overweight
    Piper Sandler
    7/12/2021$280.00Neutral → Buy
    Guggenheim
    More analyst ratings

    $HSKA
    Financials

    Live finance-specific insights

    See more
    • Heska Corporation Reports Fourth Quarter and Full Year 2022 Results

      Full Year Sales $257.3 Million, Full Year Gross Margin Up 150 Basis Points to 43.2% Full Year North America Lab Consumables Sales Up 8.7%, Total Active Subscriptions Up 18% LOVELAND, Colo., Feb. 28, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its fourth quarter and full year ended December 31, 2022. Fourth Quarter and Full Year 2022 and Year Over Year ("YOY") Metrics $ in mi

      2/28/23 8:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Heska Fourth Quarter and Full Year 2022 Financial Results and Earnings Call Scheduled for February 28, 2023

      LOVELAND, Colo., Feb. 8, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its fourth quarter and full year 2022 financial performance in a press release before the market opens on Tuesday, February 28, 2023. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-877-41-6152From outside of the United States, please dial 1-201-389-

      2/8/23 8:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Heska Corporation Completes Acquisition of LightDeck Diagnostics

      LOVELAND, Colo., Jan. 3, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, today announced the completion of acquisition of 100% of the shares of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in planar waveguide fluorescence immunoassay diagnostics with strong manufacturing capabilities and research and development expertise (the "Acquisition").  The Acquisition, which was first announced on September 12, 2022, represent

      1/3/23 8:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    SEC Filings

    See more
    • SEC Form 15-12G filed by Heska Corporation

      15-12G - HESKA CORP (0001038133) (Filer)

      6/23/23 6:01:38 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Heska Corporation

      EFFECT - HESKA CORP (0001038133) (Filer)

      6/14/23 12:15:09 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Heska Corporation

      EFFECT - HESKA CORP (0001038133) (Filer)

      6/14/23 12:15:13 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Leadership Updates

    Live Leadership Updates

    See more
    • Heska Corporation Elects Dr. Joachim Hasenmaier to Board of Directors

      LOVELAND, Colo., Jan. 12, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, appointed Dr. Joachim Hasenmaier, the former head of Boehringer Ingelheim Animal Health, to the Company's Board of Directors, effective January 11, 2021. Dr. Joachim Hasenmaier most recently served as a member of the board of managing directors of Boehringer Ingelheim, a world-leading, research-driven pharmaceutical company, where he oversaw the animal health and consumer healthcare businesses. Previously, as head of animal health of Boehringer Ingelheim, Dr. Hasenmaier led the rapid growth and expansion

      1/12/21 4:30:00 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bee Vaccine Pioneer Dalan Secures $4.5M to Fuel Global Expansion and Product Development

      Key Points: $4.5 million in Series Seed 3 funding, led by Prime Movers Lab with participation from At One Ventures, bringing the company's total funding to $10 million. The funding will accelerate Dalan's product pipeline and facilitate its global expansion, aiming to protect the health of honeybees and secure the global food supply. Dalan Animal Health, Inc. ("Dalan"), a pioneering biotech company in insect health, today announced the successful closure of a $4.5 million Series Seed 3 funding round. The round was led by Prime Movers Lab with participation from At One Ventures, bringing Dalan's total funding to $10 million. The additional funding will enable Dalan to expedite its

      6/27/23 9:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • eXp World Holdings & Privia Health Group Set to Join S&P SmallCap 600

      NEW YORK, June 7, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, June 14: eXp World Holdings Inc. (NASD: EXPI) will replace Heska Corp. (NASD: HSKA). Mars Inc. is acquiring Heska in a deal expected to be completed soon pending final conditions.Privia Health Group Inc. (NASD: PRVA) will replace Ruth's Hospitality Group Inc. (NASD: RUTH). S&P 500 constituent Darden Restaurants Inc. (NYSE:DRI) is acquiring Ruth's Hospitality Group in a deal expected to be completed soon pending final conditions.Following is a summary of the changes that will take place prior to the open of trading on the

      6/7/23 6:37:00 PM ET
      $DRI
      $EXPI
      $HSKA
      $PRVA
      Restaurants
      Consumer Discretionary
      Real Estate
      Finance
    • Dalan Animal Health Ships First Honey Bee Vaccine to Tauzer Apiaries, Potentially Protecting 25 Million Bees.

      Dalan Animal Health, Inc. ("Dalan"), the biotech company pioneering insect health with the world's first honey bee vaccine, is proud to announce its first product shipment to a commercial beekeeper. The shipment is for Trevor Tauzer of Tauzer Apiaries in California and contains 500 doses, potentially protecting 25 million bees at an average of 50,000 bees per hive. This milestone follows the U.S. Department of Agriculture (USDA) granting a conditional license to Dalan's first-in-class honeybee vaccine earlier this year. The vaccine is indicated to protect honeybees against the devastating American Foulbrood disease caused by the bacteria Paenibacillus larvae. Honeybees are a critical co

      5/23/23 7:20:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Heska Corp downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Heska Corp from Equal-Weight to Underweight and set a new price target of $58.00

      1/6/23 8:09:57 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Morgan Stanley reiterated coverage on Heska with a new price target

      Morgan Stanley reiterated coverage of Heska with a rating of Equal-Weight and set a new price target of $161.00 from $190.00 previously

      3/1/22 9:56:21 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • JP Morgan reiterated coverage on Heska with a new price target

      JP Morgan reiterated coverage of Heska with a rating of Overweight and set a new price target of $250.00 from $300.00 previously

      2/23/22 8:14:03 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Heska Corporation (Amendment)

      SC 13G/A - HESKA CORP (0001038133) (Subject)

      4/10/23 2:50:12 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Heska Corporation (Amendment)

      SC 13G/A - HESKA CORP (0001038133) (Subject)

      2/14/23 4:07:17 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Heska Corporation (Amendment)

      SC 13G/A - HESKA CORP (0001038133) (Subject)

      2/10/23 10:12:43 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Maples Sharon J.

      4 - HESKA CORP (0001038133) (Issuer)

      6/14/23 6:27:54 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Eyl Steven M.

      4 - HESKA CORP (0001038133) (Issuer)

      6/14/23 6:27:55 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Hasenmaier Joachim A.

      4 - HESKA CORP (0001038133) (Issuer)

      6/14/23 6:27:56 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care